Gland Pharma Annual report FY22 is out.
Here are the key highlights
<<A detailed thread 🧵>>
Here are the key highlights
<<A detailed thread 🧵>>
1. Overview
🎛️ Consolidated nos
Revenue: Rs 4400 cr (+27%)
EBITDA Rs 1734 cr (+21%)
PAT Rs 1211 cr (+ 22%)
🎛️Finished formulation capacity: ~1,000 million units from 800 mn units in FY21
🎛️ Consolidated nos
Revenue: Rs 4400 cr (+27%)
EBITDA Rs 1734 cr (+21%)
PAT Rs 1211 cr (+ 22%)
🎛️Finished formulation capacity: ~1,000 million units from 800 mn units in FY21
2. Market & Growth
~Revenue growth of 16% across core markets of the US, Canada, Europe, and Australia.
~13% growth in the US market
~Rest of the World grew by 55%
~ The Indian market also witnessed significant revenue growth of 60%.
~Revenue growth of 16% across core markets of the US, Canada, Europe, and Australia.
~13% growth in the US market
~Rest of the World grew by 55%
~ The Indian market also witnessed significant revenue growth of 60%.
3.Shareholding Pattern
~Float coming down
~institutional holding grew in Jun qtr from 23% to 27% further
~Nicmac (an erstwhile promoter ) holding reduced to < 2% (sold max in Q122)
~promoters holding reduced marginally
~Float coming down
~institutional holding grew in Jun qtr from 23% to 27% further
~Nicmac (an erstwhile promoter ) holding reduced to < 2% (sold max in Q122)
~promoters holding reduced marginally
5. Growth across markets
Look at the 3 year CAGR across markets .
It is an impressive growth
Look at the 3 year CAGR across markets .
It is an impressive growth
6. Key products & launches
Core market
~Micafungin Sodium
~Ketorolac Tromethamine
~Heparin Sodium
~Ziprasidone
~Dexmedetomidine
Domestic launches FY22
~Caspofungin Acetate
~Enoxaparin Sodium (Multi- Dose Cartridge with Pen Device)
Core market
~Micafungin Sodium
~Ketorolac Tromethamine
~Heparin Sodium
~Ziprasidone
~Dexmedetomidine
Domestic launches FY22
~Caspofungin Acetate
~Enoxaparin Sodium (Multi- Dose Cartridge with Pen Device)
7. Circular economy
Shifted to piped #naturalgas at 1 facility
#GAIL AR22 also highlighted this as a key trend to watch out for
#RIL AR22 also putting thrust on natural gas usage going forward
Shifted to piped #naturalgas at 1 facility
#GAIL AR22 also highlighted this as a key trend to watch out for
#RIL AR22 also putting thrust on natural gas usage going forward
8. Ecosystem and therapy practice
~good slide to spent time on
~good slide to spent time on
9. Intelectual capital input vs output
10.Facilities & approvals
~4 USFDA approved facilities
~At Pashamylaram, Hyderabad installed 4 new lines leading to increase in capacity by > 200 million units
~will aid in the development of complex injectables pipeline (suspensions, hormones, and emulsion-based products)
~4 USFDA approved facilities
~At Pashamylaram, Hyderabad installed 4 new lines leading to increase in capacity by > 200 million units
~will aid in the development of complex injectables pipeline (suspensions, hormones, and emulsion-based products)
11. API & bio-similar
~4 API plants (3 USFDA approved)
~Biosimilar capped ongoing
~4 API plants (3 USFDA approved)
~Biosimilar capped ongoing
12. Business model wise revenue break top and growth
~For the first time gland disclosed these break ups and growth rates
~B2B IP led model is the main growth engine with ~30% growth
~For the first time gland disclosed these break ups and growth rates
~B2B IP led model is the main growth engine with ~30% growth
Loading suggestions...